Phase III regenerative medicine trial for heart failure cleared to start
This article was originally published in Clinica
Executive Summary
A Phase III trial of a regenerative medicine for heart failure, highlighted in Clinica recently, has been cleared to start by Belgian regulators. Cardio3 BioSciences' Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European trial for C3BS-CQR-1, an autologous stem cell therapy for heart failure, which the firm gave details of in August, can now begin (www.clinica.co.uk, 20 August 2012).